Table of Contents
Chapter 1. Competitive Landscape of Drug Delivery Devices
1.1. Introduction
1.2. Key Players Product Overview
1.2.1. Johnson & Johnson Services, Inc.
1.2.2. Stevanato Group
1.2.3. Gerresheimer
1.2.4. SHL Medical
1.2.5. F. Hoffmann-La Roche, Ltd.
1.2.6. Novartis AG
1.2.7. BD
1.2.8. Bayer AG
1.2.9. uniQure N.V.
1.2.10. Pfizer, Inc.
1.2.11. Sibiono GeneTech Co. Ltd.
1.3. R&D Landscape of the following companies
1.3.1. Pfizer
1.3.1.1. R&D Pipeline
1.3.1.2. Number of Projects
1.3.1.3. Description
1.3.2. F. Hoffmann-La Roche Ltd.
1.3.2.1. R&D Pipeline
1.3.2.2. Number of Projects
1.3.2.3. Description
1.3.3. Johnson and Johnson Services
1.3.3.1. R&D Pipeline
1.3.3.2. Number of Projects
1.3.3.3. Description
1.3.4. Gerresheimer
1.3.4.1. R&D Pipeline
1.3.4.2. Number of Projects
1.3.4.3. Description
1.3.5. Stevanato Group
1.3.5.1. R&D Pipeline
1.3.5.2. Number of Projects
1.3.5.3. Description
1.3.6. BD
1.3.6.1. R&D Pipeline
1.3.6.2. Number of Projects
1.3.6.3. Description
1.3.7. SHL Medical
1.3.7.1. R&D Pipeline
1.3.7.2. Number of Projects
1.3.7.3. Description
1.4. Emerging Startups in Drug Delivery
1.4.1. Rapid Dose Therapeutics
1.4.2. Toralgen
1.4.3. CyCa OncoSolutions
1.4.4. Zylo
1.4.5. Technology Scientific
1.5. Emerging Innovations in Drug Delivery Devices: Revolutionizing Precision and Patient Experience
1.5.1. Molecular Devices and Targeted Drug Delivery
1.5.2. Advanced Injectable Systems and Patient-Centric Design
1.6. Global Expansion and Capacity Building
1.7. Conclusion